tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

HCM Stock Latest News

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
Press ReleasesHUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
12d ago
HCM
Hutchmed withdraws NDA in China for fruquintinib in combination with paclitaxel
PremiumThe Fly
Hutchmed withdraws NDA in China for fruquintinib in combination with paclitaxel
21d ago
HCM
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
PremiumPress Releases
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
22d ago
HCM
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
PremiumPress Releases
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
1M ago
HCM
Hutchmed reiterates 2024 guidance for Oncology/Immunology revenue $300M-$400M
PremiumThe Fly
Hutchmed reiterates 2024 guidance for Oncology/Immunology revenue $300M-$400M
2M ago
HCM
Hutchmed reports 1H revenue $305.7M vs. $532.9M last year
PremiumThe FlyHutchmed reports 1H revenue $305.7M vs. $532.9M last year
2M ago
HCM
HUTCHMED’s Cancer Drug Fast-Tracked in China
Premium
Company Announcements
HUTCHMED’s Cancer Drug Fast-Tracked in China
3M ago
6K
HCM
HUTCHMED to Announce 2024 Half-Year Financial Results
Premium
Press Releases
HUTCHMED to Announce 2024 Half-Year Financial Results
3M ago
HCM
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
PremiumPress Releases
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
3M ago
HCM
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
PremiumPress Releases
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
3M ago
HCM
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
PremiumPress Releases
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
3M ago
HCM
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
PremiumPress Releases
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
4M ago
HCM
Hutchmed announces FRUTIGA results published in Nature Medicine
PremiumThe FlyHutchmed announces FRUTIGA results published in Nature Medicine
4M ago
HCM
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
Premium
Press Releases
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
4M ago
HCM
Hutchmed initiated with a Buy at HSBC
Premium
The Fly
Hutchmed initiated with a Buy at HSBC
4M ago
HCM
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
PremiumPress Releases
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
4M ago
HCM
HUTCHMED’s Breakthroughs in Hematology Spotlighted
PremiumCompany Announcements
HUTCHMED’s Breakthroughs in Hematology Spotlighted
4M ago
6K
HCM
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
PremiumPress Releases
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
4M ago
HCM
Hutchmed chairman Simon To retires, Dan Eldar to succeed
PremiumThe Fly
Hutchmed chairman Simon To retires, Dan Eldar to succeed
4M ago
HCM
Hutchmed initiated with a Buy at Bocom
PremiumThe FlyHutchmed initiated with a Buy at Bocom
4M ago
HCM
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
Premium
Press Releases
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
4M ago
HCM
HUTCHMED Launches Innovative Cancer Treatment Trial
Premium
Company Announcements
HUTCHMED Launches Innovative Cancer Treatment Trial
4M ago
6K
HCM

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >